Compare · NGNE vs NVO
NGNE vs NVO
Side-by-side comparison of Neurogene Inc. (NGNE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NGNE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 435.5x NGNE ($422.1M).
- Over the past year, NGNE is up 86.5% and NVO is down 34.2% - NGNE leads by 120.8 points.
- NGNE has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for NGNE).
- Company
- Neurogene Inc.
- Novo Nordisk A/S
- Price
- $27.03+0.24%
- $41.18+6.93%
- Market cap
- $422.1M
- $183.82B
- 1M return
- +21.76%
- +13.32%
- 1Y return
- +86.54%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 6
- 5
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NGNE
- SEC Form 3 filed by new insider Shafer Christina
- Neurogene Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
- SEC Form DEF 14A filed by Neurogene Inc.
- SEC Form DEFA14A filed by Neurogene Inc.
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Cvijic Christine Mikail
- SEC Form 4 filed by Jordan Julie
- SEC Form 4 filed by Mcminn Rachel
- SEC Form S-8 filed by Neurogene Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S